About Spruce Biosciences
Spruce is committed to transforming the lives of patients living with rare endocrine disorders. Spruce’s wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage clinical trials in adult patients with classic congenital adrenal hyperplasia (CAH).